Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Item
http://www.wikidata.org/entity/Q33633424
Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the StartTyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Integrating mHealth in Oncology: Experience in the Province of TrentoProof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled TrialMonoclonal antibodies for treating gastric cancer: promises and pitfalls.Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.Sunitinib Possible Sex-Divergent Therapeutic Outcomes.The high price of anticancer drugs: origins, implications, barriers, solutions.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.
P2860

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.

Item
http://www.wikidata.org/entity/Q33633424
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@ast
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@en
type
label
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@ast
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@en
prefLabel
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@ast
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Oral anticancer drugs: how lim ...... ials and efficacy in patients.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932